Canadian biopharmaceutical company Bioniche Life Sciences Inc. has two canine cancer biologics in the pipeline and expects one to hit the market by July of this year, the Belleville, Ontario-based company reported.
Both products are based on the company’s mycobacterial cell wall technology used in Bioniche’s Equimune I.V. immunotherapeutic agent for the treatment of viral equine respiratory tract infections in horses.
The canine cancer biologic scheduled for a 2012 launch, Immunocidin, is pending regulatory approval in Canada and the United States as an immunotherapy for the intratumoral treatment of mixed mammary tumor and mammary adenocarcinoma in dogs.
The other biologic, currently unnamed, is an intravenous therapy designed to restore white blood cell levels in dogs following chemotherapy treatment. Bioniche expects to complete testing of the product over the next six months, at which time it will seek regulatory approval in North America, followed by Australia and Europe.